HPLC · CoA
When Will Retatrutide Be Available in Australia?
Legal · 6 min read · Updated 30 September 2026
When will retatrutide be available in Australia as an approved medicine is a question no one can answer yet, because no approval date exists. Its phase 3 clinical programme has not finished. Before it could be registered, those trials must finish, a sponsor must lodge an application with the Therapeutic Goods Administration (TGA), and the TGA must complete its evaluation, a process that generally takes a year or more after submission. At present retatrutide has no ARTG entry, and local supply is confined to research-grade material intended for in-vitro laboratory work.
Is Retatrutide Available in Australia Right Now?
Retatrutide is available in Australia right now only as a research chemical for laboratory study, not as a medicine. Research-grade material can be purchased by laboratories and researchers 18 years or older for laboratory studies such as receptor assays, stability studies and analytical method development. It is not registered for any therapeutic purpose, it is not for human or veterinary use, and it must not be supplied or represented as a therapeutic good. That distinction between research supply and medicine supply is the core of the legal position.
Is Retatrutide TGA Approved?
Retatrutide is not TGA approved. A search of the ARTG returns no entry for retatrutide or for its development code, LY3437943, because no sponsor has completed the registration pathway. In Australia a medicine may only be lawfully marketed for therapeutic use once it is entered on the ARTG, which requires evidence of quality, safety and efficacy to be assessed by the TGA. Until that happens, retatrutide sits outside the therapeutic goods system entirely and can only be supplied as a research material.
What Phase Is Retatrutide In?
Retatrutide is in phase 3, the final stage of clinical development before a registration application. Phase 3 programmes enrol large numbers of participants across many countries and run for extended periods, often with separate trials for different study populations. Its developer began registering these trials in 2023, and several remain in progress. The published record up to that point is set out by phase and year in the timeline table.
Has Retatrutide Passed Phase 3?
Retatrutide has not completed its phase 3 programme as a whole, and completion of individual trials does not by itself make a compound available. After the pivotal trials read out, the full data set is analysed, compiled into a dossier and lodged with each regulator separately. Each agency then runs its own evaluation. A result from one trial, reported in a press release or at a conference, is a step in that sequence rather than an approval. That is why the answer to when will retatrutide be available in Australia depends on dossier timing, not on any single trial result.
Retatrutide Research Timeline by Phase and Year
The table lists the published record by stage, journal and year. It is a reference for literature review and deliberately leaves out outcome figures.
| Year | Stage | Where it was published or registered |
|---|---|---|
| 2022 | Discovery and first clinical pharmacology | Cell Metabolism |
| 2022 | Phase 1b | The Lancet |
| 2023 | Phase 2 | New England Journal of Medicine |
| 2023 | Phase 2 | The Lancet |
| 2023 onwards | Phase 3 programme registered | international trial registries |
| 2024 | Phase 2 liver fat substudy | Nature Medicine |
| In progress | Phase 3 trials running | results not yet complete |
Full study summaries are grouped in the retatrutide research library.
What Has to Happen Before Retatrutide Can Be Registered in Australia?
Before retatrutide can be registered in Australia, a sponsor must submit a complete application to the TGA and the TGA must accept and evaluate it. The general sequence for a new chemical entity looks like this.
- **Trial completion:** the phase 3 programme finishes and the data are analysed.
- **Submission:** a sponsor with an Australian presence lodges a registration dossier covering quality, nonclinical and clinical data.
- **Evaluation:** TGA assessors review the dossier and may seek expert committee advice. This stage generally runs for a year or more.
- **Decision and ARTG entry:** if approved, the medicine is entered on the ARTG with its approved indications and conditions.
- **Scheduling:** the substance is placed in the appropriate schedule of the Poisons Standard, which governs how it can be supplied.
Some agencies overseas may act earlier or later than the TGA, and an approval elsewhere does not register a medicine here.
Is Retatrutide Approved Anywhere?
Retatrutide remains an investigational compound, and we are not aware of it holding marketing approval from the TGA; readers checking its status in another country should consult that regulator's public register directly. Regulatory status changes over time, so an official register is always more reliable than a secondary source, including this one.
How Do the Poisons Standard and State Laws Apply?
The Poisons Standard (the SUSMP) classifies substances into schedules that control how they can be sold, and each state and territory gives it force through its own poisons legislation. Peptide hormone analogues can fall within these schedules, and the rules for possession and supply differ between jurisdictions. The conditions of sale appear in our research use policy, and whether research peptides are legal in Australia explains the framework in more detail. None of it is legal advice; researchers should check the current Poisons Standard and their own state or territory law.
How Do You Get Retatrutide in Australia for Research?
You get retatrutide in Australia for research by purchasing research-grade material from a supplier that sells it for in-vitro laboratory use only. We supply Retatrutide vials in 10mg, 15mg, 20mg and 30mg as lyophilised powder, dispatched from Australian stock with tracking. Each batch is HPLC tested with purity of 98% or higher and identity confirmed by mass spectrometry, and a certificate of analysis accompanies every lot. For a first order, our recommendation is the retatrutide starter kit with bacteriostatic water, which includes the diluent needed for reconstitution. Related compounds are grouped in the metabolic peptide category, and the full catalogue is in the Macropus Peptides shop.
Questions about when will retatrutide be available in australia
Written by the Macropus Peptides technical team for in-vitro laboratory research reference. Not medical advice; products are not for human or veterinary use and are sold to buyers aged 18 and over.